Medical Device PMS in China

Effective post-market surveillance (PMS) is essential for maintaining the safety and performance of medical devices after they have been introduced to the Chinese market. Under China's evolving medical device regulation, the National Medical Products Administration (NMPA) mandates that In-Vitro Diagnostic (IVD) and medical device manufacturers establish and maintain a compliant PMS system to ensure long-term safety, effectiveness, and market access.

Medical Device Regulations
Quality Management Requirements

What is Post-Market Surveillance (PMS)?

Post-market surveillance (PMS) refers to the ongoing process of monitoring the clinical performance and device performance of medical devices and IVDs once they are commercially available. In contrast to pre-market clinical trials, PMS collects real-world clinical data through user feedback, adverse events, and market observations to ensure ongoing medical device safety.

In China, a robust post-market surveillance framework is legally required and forms an essential part of the broader quality management system. It plays a critical role in identifying risks that could lead to serious adverse health consequences or serious incidents, particularly for high-risk Class III devices.

PMS in China: Regulatory Overview

The NMPA has significantly expanded its focus on post-market surveillance, introducing regulations that emphasize real-world data, proactive risk control, and continuous compliance. Under these regulations, manufacturers must:

Ensure timely adverse event reporting (AE) through China’s National Medical Device Adverse Event Monitoring System (NMDAEM System).
Submit periodic safety update reports known in China as Periodic Risk Evaluation Reports (PRER) based on cumulative market data.
Conduct annual QMS self-assessments, including detailed reports submitted to NMPA.
Maintain a Good Manufacturing Practice (GMP) system and prepare for regular inspections.
Regularly update technical documentation to reflect changes in local standards, ensuring medical device safety and performance.
File change notifications and certificate renewals on time—typically every five years—to avoid regulatory delays or product holds.

Manufacturers have specific responsibilities under NMPA regulations to ensure compliance with these requirements, including the implementation of post-market surveillance plans and maintaining the safety and performance of medical devices.

Noncompliance with these regulatory requirements may lead to enforcement actions, including certificate suspension or market withdrawal.

Core Components of a PMS System under the NMPA

To effectively meet China’s PMS requirements, IVD and medical device manufacturers must implement a structured system encompassing the following components:

1. PMS Plan Development

Every manufacturer must prepare a comprehensive PMS plan or post-market surveillance plan tailored to each product. This plan outlines procedures for data collection, data analysis, reporting, and initiating corrective and preventive actions (CAPA). A comprehensive PMS plan outlines data sources, analysis methods, and action thresholds. It should be regularly reviewed and updated to reflect current NMPA regulations and device performance insights.

2. Adverse Event Monitoring

Daily monitoring of the NMDAEM System enables early identification of risks, especially for events that could result in adverse health consequences. AE reports must be reviewed, translated if necessary, and submitted to NMPA within prescribed timelines.

3. PRER & PMS Reports

Manufacturers of Class II and III devices must compile and submit PRERs (PMS reports) that summarize cumulative risk data, trend analysis, and any resulting risk mitigations.

4. Corrective & Preventive Actions (CAPA)

CAPAs are initiated in response to identified issues. These actions must address root causes, be well-documented, and include follow-up monitoring to verify effectiveness.

5. Label & IFU Compliance

Chinese-language labels and Instructions for Use (IFUs) must be reviewed to confirm they meet the NMPA’s content and formatting standards, including accurate legal agent and manufacturer details.

6. UDI & Traceability

For devices subject to China’s UDI regulation, manufacturers must maintain updated UDI-DI codes in the NMPA database and ensure traceability throughout the supply chain.

7. Annual Summary Reports

An annual summary of all PMS activities, including adverse event trends and effectiveness of CAPAs, must be compiled and retained for audit readiness.

8. Integration with QMS

PMS processes should be embedded within the organization’s ISO 13485-certified QMS to ensure a seamless approach to compliance and continuous improvement.

Common Challenges in China PMS Compliance

PMS implementation in China is not without obstacles. IVD and medical device companies often encounter:

Fragmented or manual PMS data systems
Difficulty accessing AE data in Chinese
Complex digital platforms (e.g., E-RPS, NMDAEM, UDI systems)
Tight timelines for PRER submission and renewals

Solutions include:

Designating a reliable NMPA Legal Agent with system access
Standardizing AE handling workflows and translation procedures
Automating internal reminders for regulatory deadlines
Regularly training staff on evolving regulatory expectations.
China Post Market Surveillance Requirements

Post-Market Surveillance as Part of a QMS

Embedding PMS into the QMS framework ensures consistent, organization-wide awareness of safety obligations. A QMS is essential for meeting international standards like ISO 13485:2016, ensuring compliance with regulatory obligations. This alignment supports:

Faster response to safety issues
More accurate documentation for inspections or renewals
Improved product lifecycle planning
Stronger alignment with both ISO and NMPA requirements

Many manufacturers report better regulatory performance and reduced product release delays after integrating PMS activities into their core QMS.

For medical device companies in China, post-market surveillance is more than a compliance requirement, it is a strategic pillar of safe, effective, and sustainable operations. By aligning with NMPA’s PMS framework and integrating surveillance activities into your QMS, you enhance regulatory readiness, improve product safety, and strengthen patient trust. Active monitoring and a proactive, well-documented PMS system are the foundation for long-term success in the Chinese medical device market.

Our Post-Market Surveillance Services for NMPA Compliance

To help you perform post market surveillance activities for China, below is a non-exhaustive list 
of services we offer. We also help you build a proactive PMS strategy:

QMS Self-Assessment 
Support

Annual report reminders, bilingual templates, review, and submission to NMPA.

Periodic Risk Evaluation (PRER)

Guidance, review, and timely submission of PRERs in line with NMPA requirements.

Adverse Event Monitoring & Response

Daily NMDAEM system monitoring, full AE handling, submission, and tracking.

Annual AE Summary & Analysis

Yearly review and reporting of all adverse events to support risk management.

Regulatory News 
& Updates

Regular alerts on new NMPA regulations and standards affecting your product certificates.

Recall & UDI Support

Representation during recalls and assistance with UDI-DI transfers in the NMPA database.

Label & IFU Compliance 
Checks

Review of Chinese labeling and IFU content to meet NMPA standards.

Insurance & Procurement Reporting

Submission of AE and risk reports for medical insurance and centralized bidding.

It is crucial for any company to manage and improve their PMS processes efficiently, as this impacts the overall safety and effectiveness of the devices they produce.

Useful Articles

View More

Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Understand MFDS clinical trial requirements for digital medical devices, including real-world evidence, data-based studies, and software validation expectations.

June 2, 2026
Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Cisema Expands into South Korea

Supporting foreign manufacturers entering South Korea with regulatory services for medical devices, IVDs, and quasi-drugs.

June 1, 2026
Cisema Expands into South Korea
Seoul skyline in the early evening

Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

May 20, 2026
Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
A healthcare worker in a white coat checks a seated patient’s blood pressure while another medical staff member in green scrubs stands nearby holding a clipboard in a bright clinic setting.

Medical Device Market Access for Thailand, Indonesia, and the Philippines

Cisema offers regulatory insight and market access strategy for medical devices in Thailand, Indonesia, and the Philippines.

May 15, 2026
Medical Device Market Access for Thailand, Indonesia, and the Philippines
Medical Device Market Access for Thailand, Indonesia, and the Philippines

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

May 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Three masked surgical staff in green operating room attire stand with folded arms beside a patient lying on an operating table, with medical monitors and X-ray images displayed in a dimly lit operating room.”

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

May 14, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive. We also help your company conduct postmarket surveillance to ensure regulatory compliance and device safety.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements. 

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China. Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs. 

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.  

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.

Our experts prepare and assist you for official NMPA inspections.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Latest Insights

View More

MFDS Issues 2025 Korea Medical Device Regulatory Update Report

Summary of 2025 MFDS trends covering medical device approvals, import dynamics, and the shift toward AI and software-based regulation.

June 2, 2026
MFDS Issues 2025 Korea Medical Device Regulatory Update Report

China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

China’s SAMR has released draft advertising review measures that would increase oversight of livestreaming and digital marketing while streamlining certain compliance requirements for regulated products.

June 1, 2026
China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers

The updated GN-00 guidance reduces classification uncertainty and creates clearer MDACS pathways for injectable dermal fillers in Hong Kong.

May 29, 2026
Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers
Stock photo of a Chinese woman seated in a modern medical aesthetics clinic just seconds before receiving dermal filler treatment

Malaysia MDA Updates Medical Device Definitions, Special Access, & Legacy Device Rules 

Malaysia’s MDA has issued major updates affecting medical device classification, special access exemptions, and management of obsolete and discontinued devices under the Medical Device Act 2012

May 27, 2026
Malaysia MDA Updates Medical Device Definitions, Special Access, & Legacy Device Rules 
Ultra-photorealistic stock photo of a modern patient monitoring device in active clinical use inside a contemporary Malaysian hospital room.

China Launches Trial Medical Device Vigilance Framework Across 17 Pilot Regions

New measures define vigilance management, inspections, PSURs, trend reporting, and reporting requirements in 17 pilot regions

May 20, 2026
China Launches Trial Medical Device Vigilance Framework Across 17 Pilot Regions

China Launches National AI Roadmap for Pharmaceuticals, Medical Devices, & Cosmetics Supervision

China’s NMPA released a AI roadmap for smarter supervision across drugs, medical devices, and cosmetics regulation, covering AI-supported review, inspections, traceability, risk monitoring, and digital governance through 2035.

May 15, 2026
China Launches National AI Roadmap for Pharmaceuticals, Medical Devices, & Cosmetics Supervision
A business professional sits at a conference table using a laptop displaying a glowing digital brain graphic with the text “AI.” The setting appears to be a modern office with large windows and blurred city buildings in the background.
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can assist your PMS activities for your medical device or IVD in China. Our efforts are focused on continuously monitoring and collecting data for China compliance. Request a free consultation for efficient PMS and risk management to enhance the overall safety and effectiveness of your devices.

Request Proposal